This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(343)
- Annex to CHMP highlights(0)
- Annual Report(18)
- Application withdrawal assessment report(3)
- Committee meeting report(230)
- COVID-19 vaccine safety update(0)
- Direct healthcare professional communication(0)
- EPAR - All authorised presentations(13)
- EPAR - Amended Product Information(0)
- EPAR - Assessment report - Variation(435)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(2)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(0)
- EPAR - Conditions imposed on member states for safe and effective use(1)
- EPAR - Full risk management plan(0)
- EPAR - Overview(1)
- EPAR - Paediatric investigation plan compliance statement(78)
- EPAR - Procedural steps taken and scientific information after authorisation(10)
- EPAR - Procedural steps taken before authorisation(4)
- EPAR - Product Information(12)
- EPAR - Public assessment report(10)
- EPAR - Risk-management-plan summary(6)
- EPAR - Scientific conclusion(14)
- EPAR - Scientific Discussion(5)
- EPAR - Scientific Discussion - Variation(4)
- EPAR - Steps taken after authorisation when a cutoff date has been used(2)
- Herbal - Call for data(2)
- Herbal - Herbal monograph(2)
- Herbal - HMPC assessment report(4)
- Herbal - HMPC opinion on a European Union herbal monograph(0)
- Herbal - List of references supporting the assessment report(5)
- Herbal - Overview of comments received during consultation(2)
- Herbal - Summary of assessment report for the public(0)
- Herbal – European Union herbal monograph(1)
- Herbal – European Union list entry(0)
- Leaflet(3)
- Maximum Residue Limits - Divergent opinion(0)
- Maximum Residue Limits - Opinion(0)
- Maximum Residue Limits - Report(0)
- Maximum Residue Limits - Summary of opinion(0)
- Medicine QA(29)
- Medicines under additional monitoring(0)
- Minutes(225)
- Newsletter(13)
- Opinion outside EU - All presentations(0)
- Opinion outside EU - Assessment report - Variation(0)
- Opinion outside EU - Medicine questions and answers(0)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(0)
- Opinion outside EU - Procedural steps taken before opinion(0)
- Opinion outside EU - Product information(0)
- Opinion outside EU - Public assessment report(0)
- Opinion outside EU - Risk-management-plan summary(0)
- Opinion outside EU - Scientific discussion(0)
- Opinion outside EU - Summary for the public(0)
- Opinion outside EU - Summary of opinion(0)
- Opinion outside EU - Summary of opinion - Initial authorisation(0)
- Opinion outside EU - Withdrawal assessment report(0)
- Orphan designation(41)
- Orphan review(1)
- Other(367)
- Overview of comments(7)
- Parallel distribution(0)
- Periodic safety update single assessment(1)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(105)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5412)
- Position statement(0)
- PRAC recommendation on signal(1)
- Presentation(815)
- Press Release(244)
- Procurement(0)
- Public Statement(43)
- Recommendation on medication errors(1)
- Recruitment(0)
- Referrals document(238)
- Regulatory and procedural guideline(47)
- Report(80)
- Scientific guideline(69)
- Standard Operating Procedure - SOP(10)
- Summary of opinion(34)
- Summary of opinion - Initial authorisation(37)
- Supply shortage(3)
- Template or form(38)
- Withdrawal letter(4)
- Work Instruction - WIN(2)
- Work programme(12)
- Advanced therapies(1797)
- Antimicrobial resistance(270)
- Biologicals(147)
- Biosimilars(649)
- Brexit(121)
- Careers(5)
- Clinical trials(599)
- Compassionate use(17)
- Compliance and inspections(600)
- Corporate(115)
- COVID-19(899)
- Data on medicines(987)
- Early access(201)
- Fees(24)
- Generic and hybrid medicines(2185)
- Governance(707)
- Innovation(1164)
- Maximum residue limit(1001)
- Medication error(28)
- Medicines(47014)
- Medicines for use outside the EU(148)
- Medicine shortages(300)
- Mpox(39)
- (-)Paediatrics(12241)
- Parallel distribution(15)
- Pharmacovigilance(9661)
- Procurement(132)
- Product information(6316)
- Quality of medicines(224)
- Rare diseases(8242)
- Referrals(3388)
- Regulatory and procedural guidance(3520)
- Research and development(495)
- Scientific advice(290)
- Scientific guidelines(1753)
- SME(259)
- Vaccines(1501)
- Veterinary limited markets(64)
Search results (12241)
P/0480/2023 : EMA decision of 1 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for cobolimab (EMEA-003273-PIP02-22)
English (EN) (210.4 KB - PDF)
P/0422/2023 : EMA decision of 27 October 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fazirsiran (EMEA-003355-PIP01-22)
English (EN) (235.52 KB - PDF)
P/0411/2023 : EMA decision of 25 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for deucrictibant (EMEA-003090-PIP02-22)
English (EN) (319.28 KB - PDF)
PDCO minutes of the 19-22 March 2024 meeting
English (EN) (1.54 MB - PDF)
P/0559/2021 : EMA decision of 27 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for COVID-19 vaccine (ChAdOx1-S [recombinant]) (Vaxzevria), (EMEA-002862-PIP01-20-M02)
English (EN) (791.47 KB - PDF)